Yung-Jue Bang
Yung-Jue Bang
Verified email at
Cited by
Cited by
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3 …
YJ Bang, E Van Cutsem, A Feyereislova, HC Chung, L Shen, A Sawaki, ...
The Lancet 376 (9742), 687-697, 2010
Anaplastic lymphoma kinase inhibition in non–small-cell lung cancer
EL Kwak, YJ Bang, DR Camidge, AT Shaw, B Solomon, RG Maki, SHI Ou, ...
New England Journal of Medicine 363 (18), 1693-1703, 2010
Sunitinib malate for the treatment of pancreatic neuroendocrine tumors
E Raymond, L Dahan, JL Raoul, YJ Bang, I Borbath, C Lombard-Bohas, ...
New England Journal of Medicine 364 (6), 501-513, 2011
Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer
AT Shaw, SHI Ou, YJ Bang, DR Camidge, BJ Solomon, R Salgia, GJ Riely, ...
New England Journal of Medicine 371 (21), 1963-1971, 2014
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial
YJ Bang, YW Kim, HK Yang, HC Chung, YK Park, KH Lee, KW Lee, ...
The Lancet 379 (9813), 315-321, 2012
Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study
DR Camidge, YJ Bang, EL Kwak, AJ Iafrate, M Varella-Garcia, SB Fox, ...
The lancet oncology 13 (10), 1011-1019, 2012
Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair–deficient cancer: results from the phase II KEYNOTE-158 study
A Marabelle, DT Le, PA Ascierto, AM Di Giacomo, A De Jesus-Acosta, ...
Journal of Clinical Oncology 38 (1), 1, 2020
Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial
CS Fuchs, T Doi, RW Jang, K Muro, T Satoh, M Machado, W Sun, SI Jalal, ...
JAMA oncology 4 (5), e180013-e180013, 2018
Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis
AT Shaw, BY Yeap, BJ Solomon, GJ Riely, J Gainor, JA Engelman, ...
The lancet oncology 12 (11), 1004-1012, 2011
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort …
A Marabelle, M Fakih, J Lopez, M Shah, R Shapira-Frommer, ...
The Lancet Oncology 21 (10), 1353-1365, 2020
Predictive and prognostic impact of epidermal growth factor receptor mutation in non–small-cell lung cancer patients treated with gefitinib
SW Han, TY Kim, PG Hwang, S Jeong, J Kim, IS Choi, DY Oh, JH Kim, ...
Journal of clinical oncology 23 (11), 2493-2501, 2005
Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial
K Muro, HC Chung, V Shankaran, R Geva, D Catenacci, S Gupta, JP Eder, ...
The lancet oncology 17 (6), 717-726, 2016
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial
K Shitara, M Özgüroğlu, YJ Bang, M Di Bartolomeo, M Mandalà, MH Ryu, ...
The Lancet 392 (10142), 123-133, 2018
Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies
TY Kim, DW Kim, JY Chung, SG Shin, SC Kim, DS Heo, NK Kim, YJ Bang
Clinical cancer research 10 (11), 3708-3716, 2004
KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors
DS Hong, MG Fakih, JH Strickler, J Desai, GA Durm, GI Shapiro, ...
New England Journal of Medicine 383 (13), 1207-1217, 2020
Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial
SH Noh, SR Park, HK Yang, HC Chung, IJ Chung, SW Kim, HH Kim, ...
The lancet oncology 15 (12), 1389-1396, 2014
Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III study
T Satoh, RH Xu, HC Chung, GP Sun, T Doi, JM Xu, A Tsuji, Y Omuro, J Li, ...
J Clin Oncol 32 (19), 2039-2049, 2014
A transforming growth factor β receptor type II gene mutation common in colon and gastric but rare in endometrial cancers with microsatellite instability
LL Myeroff, R Parsons, SJ Kim, L Hedrick, KR Cho, K Orth, M Mathis, ...
Cancer research 55 (23), 5545-5547, 1995
Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial
K Fujitani, HK Yang, J Mizusawa, YW Kim, M Terashima, SU Han, ...
The Lancet Oncology 17 (3), 309-318, 2016
T-cell–inflamed gene-expression profile, programmed death ligand 1 expression, and tumor mutational burden predict efficacy in patients treated with pembrolizumab across 20 …
PA Ott, YJ Bang, SA Piha-Paul, ARA Razak, J Bennouna, JC Soria, ...
Journal of Clinical Oncology 37 (4), 318-327, 2019
The system can't perform the operation now. Try again later.
Articles 1–20